Cost analysis of flavocoxid compared to naproxen for management of mild to moderate OA

Current Medical Research and Opinion

Volumn 26, Issue 9, 2010, Pages 2253-2261

  Walton, Surrey M ^a   Schumock, Glen T ^a   McLain, David Andrew ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Brookwood Medical Center Birmingham   (United States)

Author keywords

Cost analysis; Decision modeling; Medical food; Osteoarthritis

Indexed keywords

AMOXICILLIN; ANTIINFLAMMATORY AGENT; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; FLAVOCOXID; LIMBREL 250; LIMBREL 500; NAPROXEN; OMEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COST BENEFIT ANALYSIS; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; GASTRIC ULCER BLEEDING; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; MEDICAL DECISION MAKING; MEDICARE; MODEL; OSTEOARTHRITIS; PATIENT COMPLIANCE; PROBABILITY; RECOMMENDED DRUG DOSE; SENSITIVITY ANALYSIS; STOMACH PERFORATION; STOMACH ULCER; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATECHIN; COMORBIDITY; COSTS AND COST ANALYSIS; DRUG COMBINATIONS; HOSPITALIZATION; HUMANS; MODELS, ECONOMIC; NAPROXEN; OSTEOARTHRITIS; SEVERITY OF ILLNESS INDEX;

EID: 77955615921     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.505545     Document Type: Article

References (27)

1. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A metaanalysis. Ann Intern Med 1991;115:787-796
2. Hootman JBJ, Helmick C, Langmaid G. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation-United States, 2003-2005. MMWR Morb Mortal Wkly Rep 2006;55:1089-1092
3. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-162
4. Conaghan PG, Dickson J, Grant RL. Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ 2008;336:502-503
5. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995;38:1541-1546
6. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 1995;38:1535-1540
7. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-1915
8. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007;15:981-1000
9. Food and Drug Administration F. FDA Requires Additional Labeling for Overthe-Counter Pain Relievers and Fever Reducers to Help Consumers Use Products Safely. 2009. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm149573.htm [Last accessed 11 November 2009]
10. Roumie CL, Choma NN, Kaltenbach L, et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf 2009;18:1053-1063
11. Burnett BP, Levy R, Cole BJ. Metabolic mechanisms in the pathogenesis of osteoarthritis. A review. J Knee Surg 2006;19:191-197
12. Altavilla D, Squadrito F, Bitto A, et al. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages. Br J Pharmacol 2009;157:1410-1418
13. Food and Drug Administration F. Medical Foods. 2009. Available at http://www.fda.gov/Food/FoodSafety/Product-SpecificInformation/MedicalFoods/ default.htm
14. Morgan SL, Baggott JE. Medical foods: products for the management of chronic diseases. Nutr Rev 2006;64:495-501
15. Burnett BP, Jia Q, Zhao Y, et al. A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food 2007;10:442-451
16. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005;112:759-770
17. Carmichael J, Shankel SW. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 1985;78:992-1000
18. Marcouiller P, Pelletier JP, Guevremont M, et al. Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis. J Rheumatol 2005;32:704-712
19. Hudson N, Balsitis M, Everitt S, et al. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:742-747
20. Levy RM, Saikovsky R, Shmidt E, et al. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. Nutr Res 2009;29:298-304
21. Levy RM, Khokhlov A, Kopenkin S, et al. Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Advances in Therapy (in review), 2010
22. Pillai L, Burnett BP, Levy RM. GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Curr Med Res Opin 2010;26:1055-1063
23. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129: 1756-1780
24. Bartholow M. Top 200 Prescription Drugs of 2009. Pharmacy Times May 11, 2010. Available at: http://www.pharmacytimes.com/issue/pharmacy/2010/May2010/ RxFocusTopDrugs-0510
25. Talley NJ. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005;129:1753-1755
26. Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum 2005;53:185-197
27. Unknown. Clinical Pharmacology: Dosing for omeprazole in H. Pylori. Gold Standard, An Elsevier Company 2010. Available at http://www. clinicalpharmacology.com/?epm=2-1 [Last accessed 27 July 2010]